Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Xiao Fang Pharmaceutical CoSHSE:603207 -0.69%41 Return-on-Tangible-Asset is 15.71% as of Jun. 2026, which is 62% below its 10-year median of 41.35. GuruFocus rates SHSE:603207 with a GF Score™ of 41/100. The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Shanghai Xiao Fang Pharmaceutical Co ranks better than 89.97% on this metric.
The historical rank and industry rank for Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:603207'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 15.96 Med: 41.35 Max: 63.29
Current: 15.96
During the past 7 years, Shanghai Xiao Fang Pharmaceutical Co's highest Return-on-Tangible-Asset was 63.29%. The lowest was 15.96%. And the median was 41.35%.
SHSE:603207's Return-on-Tangible-Asset is ranked better than 89.97% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.84
vs SHSE:603207: 15.96
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shanghai Xiao Fang Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Shanghai Xiao Fang Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Xiao Fang Pharmaceutical Co Return-on-Tangible-Asset Chart
SHSE:603207 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Xiao Fang Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.71% mean?
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) has a Return-on-Tangible-Asset of 15.71% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shanghai Xiao Fang Pharmaceutical Co and its competitors. This is 62% below median its historical median of 41.35. Over the past decade, Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 15.96 to 63.29. According to the industry distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #101 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 10%.
Is Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset too high?
Shanghai Xiao Fang Pharmaceutical Co's current Return-on-Tangible-Asset of 15.71% is 62% below median its 10-year median of 41.35. Over the past 10 years, this metric has ranged from a low of 15.96 to a high of 63.29. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.84. Shanghai Xiao Fang Pharmaceutical Co's value of 15.71% is 453.2% above this industry median. Based on the distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #101 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Xiao Fang Pharmaceutical Co has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Xiao Fang Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #101 out of 1007 companies for Return-on-Tangible-Asset. This places Shanghai Xiao Fang Pharmaceutical Co in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.84. Shanghai Xiao Fang Pharmaceutical Co's value of 15.71% is 453.2% above this benchmark. Historically, Shanghai Xiao Fang Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 15.96 to 63.29 over the past decade. While the company's 10-year median is 41.35 vs. the industry median of 2.84, Shanghai Xiao Fang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.84, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Xiao Fang Pharmaceutical Co's current Return-on-Tangible-Asset of 15.71% is 453.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shanghai Xiao Fang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Xiao Fang Pharmaceutical Co's current Return-on-Tangible-Asset is 15.71%, which is 62% below median its own 10-year median of 41.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Xiao Fang Pharmaceutical Co stock overvalued right now?
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) has a current Return-on-Tangible-Asset of 15.71%. The current Return-on-Tangible-Asset is 15.71%, which is 62% below median its 10-year median of 41.35 and 453.2% above the Drug Manufacturers industry median of 2.84. Shanghai Xiao Fang Pharmaceutical Co's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207), the current Return-on-Tangible-Asset is 15.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603207 has been successfully added to your 
